Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 16.1 %

Shares of NASDAQ:EGRX opened at $0.65 on Wednesday. The stock has a fifty day moving average of $0.69 and a 200-day moving average of $2.75. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of institutional investors have recently bought and sold shares of EGRX. Creative Planning purchased a new stake in Eagle Pharmaceuticals during the third quarter valued at about $59,000. Mackenzie Financial Corp acquired a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at $65,000. Fidelis Capital Partners LLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $71,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Eagle Pharmaceuticals during the second quarter valued at $76,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.